While the eye condition impacts 1.4 billion people worldwide, its only treatment solutions are contact lenses, glasses and surgery. Lento Bio is developing a medication for more effective, less invasive presbyopia treatment.
Through its new university partnership, James Frederich, PhD, will use his lab at FSU to help Lento develop an optimized eye medication, according to a Feb. 7 press release.
Dr. Frederich heads an NIH-funded research lab in the department of chemistry and biochemistry that focuses on building complex natural products as leads for new drugs. His lab has raised over $3 million in federal funding to date.
Dr. Frederich will also be joining Lento’s scientific advisory board, alongside ophthalmologist Mark Breazzano, MD, ophthalmologist Igor Bussel, MD, and investor Kenneth Scott.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.